Solid tumbles after latest DMD gene therapy setback

Solid Biosciences Inc. (NASDAQ:SLDB) lost $15.15 (68%) to $7.19 Thursday after reporting lower than expected microdystrophin protein levels in liver biopsies from the first three patients treated with its microdystrophin gene transfer therapy, SGT-001, in the Phase I/II IGNITE DMD trial to treat Duchenne muscular dystrophy. Solid lost $536 million in market cap in the session.

In two patients treated with 5x10^13 vg/kg SGT-001

Read the full 637 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE